A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...
In this video, Catherine S. Diefenbach, MD, discusses highlights from the 2025 Lymphoma, Leukemia & Myeloma Congress.
Pharmaceutical Technology on MSN
FDA approves AbbVie’s Epkinly to treat follicular lymphoma
The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In ...
Survival outcomes of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: Results from Latin American and United States cohorts. This is an ASCO Meeting Abstract from ...
The U.S. Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy designation to MB-105, a CD5 ...
LUND, SE / ACCESS Newswire / November 17, 2025 / BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and fir ...
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback